mekinist
novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.
duloxetine "aristo" 60 mg enterokapsler, h?rde
aristo pharma gmbh - duloxetinhydrochlorid - enterokapsler, hårde - 60 mg
duloxetin "hexal" 30 mg enterokapsler, hårde
hexal a/s - duloxetinhydrochlorid - enterokapsler, hårde - 30 mg
duloxetin "hexal" 60 mg enterokapsler, hårde
hexal a/s - duloxetinhydrochlorid - enterokapsler, hårde - 60 mg
moclostad 150 mg filmovertrukne tabletter
stada arzneimittel ag - moclobemid - filmovertrukne tabletter - 150 mg
seroxat 30 mg filmovertrukne tabletter
glaxosmithkline pharma a/s - paroxetinhydrochloridhemihydrat - filmovertrukne tabletter - 30 mg
seroxat 30 mg filmovertrukne tabletter
paranova danmark a/s - paroxetinhydrochloridhemihydrat - filmovertrukne tabletter - 30 mg
atomoxetin "mylan" 100 mg kapsler, hårde
mylan ab - atomoxetinhydrochlorid - kapsler, hårde - 100 mg
atomoxetin "mylan" 18 mg kapsler, hårde
mylan ab - atomoxetinhydrochlorid - kapsler, hårde - 18 mg
atomoxetin "mylan" 25 mg kapsler, hårde
mylan ab - atomoxetinhydrochlorid - kapsler, hårde - 25 mg